Hikma Pharmaceuticals Public annual total liabilities
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Total Liabilities Growth & History (HIK)
Hikma Pharmaceuticals Public's total liabilities was $3.06B for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.06B | $253.0M | +9.00% |
| 2024 | 2024-12-31 | $2.81B | $341.0M | +13.80% |
| 2023 | 2023-12-31 | $2.47B | $148.0M | +6.37% |
| 2022 | 2022-12-31 | $2.32B | $418.0M | +21.94% |
| 2021 | 2021-12-31 | $1.91B | −$82.0M | −4.13% |
| 2020 | 2020-12-31 | $1.99B | — | — |
Hikma Pharmaceuticals Public quarterly total liabilities
Q4.24
Q2.25
Q4.25
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.29B | $289.0M | +9.62% |
| Q4 2025 | 2025-12-31 | $3.06B | $253.0M | +9.00% |
| Q2 2025 | 2025-06-30 | $3.00B | — | — |
| Q4 2024 | 2024-12-31 | $2.81B | — | — |
Hikma Pharmaceuticals Public total liabilities trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's total liabilities increased from $1.99B to $3.06B, a change of $1.08B. The latest reported quarter, Q2 2026, shows $3.29B.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
reported and calculated total liabilities
TickerStat uses total liabilities reported in company official filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...